Twist Bioscience reported an 18% rise in Q3 2025 revenues, driven by growth in synthetic biology and next-generation sequencing sectors, prompting a modest revision of its fiscal 2025 revenue guidance to $374–376 million. Xoma Royalty Corporation acquired struggling biotechs HilleVax and Lava Therapeutics, aiming to leverage undervalued assets with milestone-based financial arrangements. Bruker announced expanded cost-cutting plans amid challenging market demand, lowering its 2025 revenue guidance, while OrbiMed closed a $1.86 billion fund focused on growth-stage healthcare investments. These financial activities highlight ongoing adjustments in the biotech investment landscape amid market headwinds.